ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 55 filers reported holding ONCOMED PHARMACEUTICALS INC in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $9,220,000 | -24.8% | 1,195,897 | +11.5% | 0.00% | -33.3% |
| Q3 2016 | $12,255,000 | +18.6% | 1,072,171 | +27.7% | 0.00% | +50.0% |
| Q2 2016 | $10,333,000 | +24.1% | 839,388 | +1.9% | 0.00% | 0.0% |
| Q1 2016 | $8,325,000 | -54.1% | 823,398 | +2.4% | 0.00% | -50.0% |
| Q4 2015 | $18,122,000 | +24.8% | 803,980 | -8.1% | 0.00% | 0.0% |
| Q3 2015 | $14,517,000 | -22.0% | 875,028 | +5.8% | 0.00% | 0.0% |
| Q2 2015 | $18,617,000 | -0.7% | 827,409 | +13.8% | 0.00% | 0.0% |
| Q1 2015 | $18,752,000 | +21.8% | 727,381 | +2.8% | 0.00% | 0.0% |
| Q4 2014 | $15,397,000 | +22.2% | 707,591 | +6.3% | 0.00% | 0.0% |
| Q3 2014 | $12,604,000 | -18.2% | 665,846 | +0.7% | 0.00% | 0.0% |
| Q2 2014 | $15,400,000 | -6.8% | 660,957 | +34.6% | 0.00% | -20.0% |
| Q1 2014 | $16,527,000 | +24.6% | 491,139 | +9.3% | 0.01% | +25.0% |
| Q4 2013 | $13,261,000 | +560.4% | 449,216 | +242.5% | 0.00% | +300.0% |
| Q3 2013 | $2,008,000 | – | 131,168 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |